GAWK (Chromogranin B 420-493)

Also called: GAWK; GAWK peptide; Chromogranin B (420-493); CgB 420-493

What it is

GAWK is a 74-amino-acid peptide corresponding to chromogranin B residues 420-493 (CHGB gene, also secretogranin-1, UniProt P05060), first isolated from human pituitary and named for its N-terminal Gly-Ala-Trp-Lys (PMID 3970711). The chromogranin-B member of the granin family, it is stored in neuroendocrine secretory granules, released by regulated (PKC/PKA/calcium) exocytosis and processed tissue-specifically (PMIDs 3200116, 19215381). Its main use is as a circulating and tissue marker of neuroendocrine tumours — raised in pancreatic islet-cell tumours, pheochromocytoma and others, complementing pancreastatin (PMIDs 2723061, 8288164). It is an endogenous research peptide and marker, not an approved medicine, and has never been given to people as a treatment.

Approval status

Research Chemical. Not a drug: Drugs@FDA and the openFDA label endpoint hold no record, and FDA GSRS and ChEMBL hold no substance record for GAWK (searched November 6, 2026). It is an endogenous chromogranin-B-derived peptide; there is no therapeutic development of GAWK itself, and no registered interventional trial of giving it to people. It is studied as a neuroendocrine secretory peptide and a tumour marker.

Dosing, as printed in the page's Recommended Dosing box

No established human dose

GAWK is an endogenous chromogranin-B-derived peptide that has never been given to people as a treatment. The human studies measure the body's own GAWK in tissue and plasma as a marker, and the rest of the work is in cells.

Educational information, not medical advice. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for "research use only" are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.

Key human evidence

The 3 human studies carded on the page (6 study cards in all):

• **GAWK is a neuroendocrine-tumour marker** (Human, 1989). Across 194 tumours and 434 plasma samples, GAWK (chromogranin-B 420-493) immunoreactivity was highest in pheochromocytoma — at least ten-fold above other tumours — and also high in carcinoid, medullary thyroid carcinoma, pancreatic and ACTH-producing lung tumours, with low levels in non-endocrine tumours. Plasma GAWK was elevated in endocrine-tumour patients (especially pancreatic) and returned to normal after tumour removal — supporting GAWK as a plasma tumour marker (a human observational study). **PMID 2723061**

• **Plasma GAWK and pancreastatin in islet-cell tumours** (Human, 1993). In 12 patients with pancreatic islet-cell tumours, plasma pancreastatin (a chromogranin-A peptide) was raised in 33% and GAWK (a chromogranin-B peptide) in 50%, with no significant correlation between the two. Gel filtration of a gastrinoma patient's plasma showed pancreastatin as a single peak but GAWK as several molecular forms — indicating the two granin peptides are complementary, independently processed tumour markers (a human observational study). **PMID 8288164**

• **GAWK distribution in human neuroendocrine tissues** (Human, 1989). In human gut, pancreas, adrenal and pituitary, GAWK immunoreactivity was localised — in the gut mainly to serotonin-containing mucosal cells (in dense-core granules) and some nerve fibres, and at the highest concentrations in the adrenal medulla and pituitary. GAWK-containing endocrine cells were also chromogranin-B-immunoreactive, giving morphological support for the precursor-product relationship between chromogranin B and GAWK (a human tissue study). **PMID 2715054**

Interactions

A PubMed search for interaction studies of this compound with any drug (November 6, 2026, 0 records) found none in people. That is not evidence that it is safe to combine with anything.

Side effects and cautions

Reported side effects	Contraindications and cautions
• No human adverse-event data exist: no published study has administered GAWK to people • The human studies measure endogenous GAWK as a neuroendocrine-tumour marker in tissue and plasma (PMIDs 2723061, 8288164) • Its own physiological function and receptor are not established (PMID 2715054) • Material sold online as 'GAWK' is an unregulated research chemical of unverified content	• Not a medicine: no FDA application or label, and no approval anywhere • No human dosing, interaction, pregnancy or long-term safety data exist for administered GAWK • It is a laboratory research peptide and a diagnostic marker, not a treatment • Its physiological signalling role is undefined

Five questions to ask

1. GAWK (Chromogranin B 420-493) is listed here as "Research Chemical". What does the evidence on this sheet mean for someone in my situation, and is there an approved treatment I should consider instead?
2. Here are the medicines and supplements I take. Do any of them interact with GAWK (Chromogranin B 420-493)? This sheet records none published, which does not mean none exist.
3. Which side effects should make me stop and call you, for example no human adverse-event data exist: no published study has administered gawk to people?
4. Do any of the cautions on this sheet apply to me, such as: Not a medicine: no FDA application or label, and no approval anywhere?
5. What should we check before I start and while I am on it (blood tests, blood pressure, weight), and how often?

Grey Peptides is a vendor-neutral encyclopedia: it sells nothing and names no seller. This sheet is educational, not medical advice, and is not a prescription.